PATIENT SATISFACTION FOR LEVONORGESTREL INTRAUTERINE SYSTEM AND NORETHISTERONE FOR TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING

Authors

  • Taqdees Naqaish
  • Farwa Rizvi
  • Ahmad Khan
  • Muhammad Afzal

Abstract

Background: Dysfunctional uterine bleeding (DUB) is a common problem with complexmanagement. It can be quite harrowing for the physicians as in most instances they are unable topinpoint the cause of abnormal bleeding even after a thorough history and physical examination. Aimwas to compare patient satisfaction for Levonorgestrel intra uterine system (LNG-IUS) andNorethisterone for the treatment of Dysfunctional Uterine Bleeding (DUB). It is Descriptive case seriesconducted in Department Obstetrics and Gynaecology, Shifa International Hospital, Islamabad fromSeptember, 2011 to September, 2012. Methods: One hundred and nineteen (119) female patients ofreproductive age Group with DUB were selected by consecutive sampling. Informed written consentwas obtained. A structural patient satisfaction questionnaire (PSQ) was used to collect informationregarding age of patients, type of method used for treatment of DUB (Levonorgestrel orNorethisterone), treatment outcome in terms of patient satisfaction scale, and decrease in bleeding after6 months. Results: The mean age of the patients was 41.03±4.415 year ranging from 28–60 years. Themean parity of women in the study was 3.22±1.188 with a range of 1–7. The satisfaction level wassignificantly (p<0.05) greater (90% versus 20%) in Group A (levonorgesterol-releasing intrauterinesystem) as compared with Group B (Norethisterone). The blood loss was significantly (p<0.05)decreased in Group A (98%) as compared with Group B (80%). The preference of continuing themethod as well as recommendation to a friend was significantly greater in Group A as compared toGroup B. Conclusion: The levonorgesterol-releasing intrauterine system (LNG-IUS) is a better choiceas compared to Norethisterone, for treatment of DUB with 90% patients highly satisfied.Keywords: Levonorgestrel, Norethisterone, patient satisfaction, treatment outcome

References

Chuong CJ, Brenner PE. Management of abnormal uterine

bleeding. Am J Obstet Gynecol 1996;175:787–92.

Albers JR, Hull SK, Wesley MA. Abnormal uterine bleeding.

Am Fam Phys 2004;69:1915–26.

Goldstein SR. Menorrhagia and abnormal bleeding before the

menopause. Best Pract Res Clin Obstet Gynaecol

;18(1):59–69.

Kilbourn CL, Richards CS. Abnormal uterine bleeding.

Diagnostic considerations, management options. Postgrad Med

;109:137–8, 141–4, 147–50.

Bongers MY, Mol BW, Brolmann HA. Current treatment of

dysfunctional uterine bleeding. Maturitas 2004;47(3):159–74.

Marjoribanks J, Lethaby A, Farquhar C; Surgery versus medical

therapy for heavy menstrual bleeding. Cochrane Database Syst

Rev 2006;(2):CD003855.

Hockey J, Veema V, Panay N. The wider role of intrauterine

progestogens. In: Studd J. (Ed). Progress in obstetrics and

Gynaecology. 1st ed. London: Elsevier;2005.p.393–402.

Milsom I. A comparison of flurbiprofen, Tranexamic acid, and a

levonorgestrel-releasing intrauterine contraceptive device in the

treatment of idiopathic menorrhagia. Am J Obstet Gynecol

;164:879–83.

Gray R. The future of hysterectomy. BJOG 2005;112:133–9.

Hurskainen R, Teperi J, Rissanen P, Aalto A, Grenman S, Kivela

A, et al. Clinical outcomes and costs with the Levonorgestrelreleasing intrauterine system or hysterectomy for treatment of

menorrhagia. Randomized trial 5-year follow up. JAMA

;291:1456–63.

NICE Guidance. Heavy menstrual bleeding. January 2007. URL:

http://www.eguidelines.co.uk/eguidelinesmain/guidelines/summaries/

obstetrics_gynaecology_urology/nice_hmb.php

Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy

menstrual bleeding. Cochrane Database Syst Rev

;2(1):CD001016.

Coulter A, Peto V, Jenkinson C. Quality of life and patient

satisfaction following treatment for menorrhagia. Fam Pract

;11:394–401.

Barrington JA, Bowen samplings P. The LN IUS in the

management of hemorrhagic. BJOG 1997;104:614–6.

Goodman A. Abnormal genital tract bleeding. Clin Cornerstone

;3(1):25–35.

Apgar BS. Dysmenorrhea and dysfunctional uterine bleeding.

Prim Care 1997;24:161–78.

Progestins: Present and Future [editorial], J Steroid Bio Chem

Molec Biol 1996;59(5–6):357–63.

Andersson K, Rybo G. Levonorgestrel-releasing intrauterine

system in the treatment of menorrhagia. BJOG 1990;97:690–4.

Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrelreleasing intrauterine system. Ann Med 1990;22:85–90.

Sowter M. New surgical treatments for menorrhagia. Lancet

;361:1456–8.

Sowter M. Menorrhagia: the role of endometrial ablation. In:

Daya S, Harrison RF, Kempers RD (Eds). Advances in Fertility

and Reproductive Medicine: Proceedings of the 18th World

Congress on Fertility and Sterility. Amsterdam, The Netherlands:

Elsevier; 2004.p.72–80.

Busfied RA, Farquhar CM, Sowter MC, Lethasy A, Sprecher M,

et al. A randomised trial comparing the LN-IUS and thermal

bloom ablation for heavy menstrual bleeding. BJOG

:113:257–63.

Chaudhri R, Rizvi F, Afzal M. Patient satisfaction of Depot

Medroxyprogesterone Acetate (dmpa-sc) injection as

contraceptive. J Coll Physicains Surg Pak 2010;60(7):536–40.

Downloads

Published

2012-03-01